News | Stents | November 10, 2017

Cordis Showcases Comprehensive Interventional Cardiology Portfolio with Coronary Stents at TCT 2017

Portfolio now includes Medinol’s Tryton Side Branch Stent and NIRxcell bare metal stent

November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now includes two coronary stents — the Tryton Side Branch Stent and Medinol’s NIRxcell, a cobalt-chromium bare metal stent (BMS). Cordis’ cardiology products were on display during the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

The recent Cardinal Health agreement with Israel-based Medinol gives Cordis exclusive rights to sell Medinol’s coronary stent portfolio in the United States. Cordis is now selling Medinol’s NIRxcell BMS and, upon Medinol receiving U.S. Food and Drug Administration (FDA) approval, Cordis will also be the exclusive distributor of the EluNIR drug-eluting stent (DES). The EluNIR DES is currently an investigational device and not approved for commercial use in the U.S.

Medinol’s NIRxcell Bare-Metal Stent and EluNIR Drug-Eluting Stent are supported by a large body of clinical data, according to the company. The NIRxcell BMS has been tested on more than 1,000 patients and found highly effective in numerous clinical trials. Data from BIONICS, a global pivotal study of 1,919 patients from 76 sites in 8 countries, was submitted to the FDA to support U.S. regulatory approval of the EluNIR DES for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR DES is currently an investigational device and not approved for commercial use in the U.S. Medinol recently received CE-mark and other regulatory clearances in Europe for the EluNIR stent.

The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the U.S., is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). The device is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt-chromium stent is deployed in the side branch artery using a standard, single-wire, balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

For more information:

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init